Intrarosa VA Coverage Pathway: How Veterans Can Access Prasterone Vaginal DHEA

What Is Intrarosa and Why Does It Matter for Women Veterans?

Intrarosa is the brand name for prasterone, a vaginal insert delivering 6.5 mg of dehydroepiandrosterone (DHEA) directly to vaginal tissue every night. It was FDA-approved in November 2016 for moderate-to-severe dyspareunia (painful sex) caused by genitourinary syndrome of menopause (GSM) in postmenopausal women.

GSM is not a niche complaint. The Menopause Society estimates that up to 84 percent of postmenopausal women experience GSM symptoms, including vaginal dryness, burning, and pain with intercourse, yet fewer than 25 percent ever receive treatment. For women veterans, who make up a fast-growing segment of VA enrollees, access to GSM therapies inside the VA system has historically lagged behind civilian care.

Prasterone works differently from vaginal estrogen. Once inserted, the DHEA molecule is converted locally in vaginal epithelial cells into both estrogens and androgens through intracrinology, meaning the hormones act at the tissue level without significant systemic absorption. In the SYNOPSIS phase III trial (n=422 postmenopausal women), nightly prasterone 6.5 mg produced statistically significant improvements in the percentage of superficial vaginal cells, the maturation value, and vaginal pH compared with placebo at 12 weeks.

This local mechanism matters if you have a history of hormone-sensitive cancer or are reluctant to use systemic hormones. Serum estradiol levels in that same trial remained within the normal postmenopausal range throughout treatment.

Who Experiences GSM and When

GSM is most pronounced after menopause, when estrogen and DHEA production from the ovaries drops sharply. But the same symptoms can appear during:

• Perimenopause, as cycles become irregular and estrogen fluctuates
• Postpartum and lactation, when estrogen is suppressed by prolactin
• Surgical menopause following oophorectomy at any age
• Chemotherapy-induced menopause or aromatase inhibitor therapy for breast cancer

If you are a woman veteran in any of these life stages and you are experiencing vaginal dryness, burning, or pain with intercourse, ask your VA primary care provider or women's health clinic specifically about GSM. The VA Women's Health Program has a designated Women's Health Program Office at every VA medical center.

How the VA Pharmacy Benefit Works for Non-Formulary Drugs

The VA National Formulary is the list of drugs VA facilities stock and dispense without extra steps. Intrarosa is not currently on the VA National Formulary as of early 2026. That does not mean you cannot get it through VA, but it does mean your provider must take additional steps.

Here is a practical framework for navigating the VA non-formulary pathway for prasterone:

Step 1: Request a Non-Formulary Exception

Your VA prescriber submits a non-formulary drug request through the VA Computerized Patient Record System (CPRS). The request must include:

• Your diagnosis (GSM with dyspareunia, ICD-10 code N95.2 or N94.1)
• Documentation that formulary alternatives (low-dose vaginal estrogen, vaginal moisturizers) were either tried and failed or are medically contraindicated for you
• Clinical justification for prasterone specifically, for example the non-estrogen mechanism for a patient who prefers to avoid exogenous estrogen

The VA Pharmacy Benefits Management (PBM) Non-Formulary Drug Request process allows each VA facility to approve non-formulary drugs for individual patients when clinical need is documented.

Step 2: Understand Prior Authorization Requirements

Some VA facilities require a Prior Authorization (PA) form in addition to or instead of the non-formulary request, depending on the Veterans Integrated Service Network (VISN). Your VA pharmacist can tell you which pathway applies at your facility.

PA criteria for GSM drugs at VA typically require:

• Confirmed diagnosis of GSM or atrophic vaginitis
• At least one documented trial of a formulary first-line option
• Prescriber attestation that the non-formulary drug is medically necessary

Step 3: Appeal If Denied

If your non-formulary request is denied, you have the right to appeal through the VA's clinical appeals process. Ask your provider for a "Prescribing Exception" and request a Patient Advocate if needed. The VA Mission Act of 2018 also allows community care referrals when VA cannot provide a specific service in a timely manner, which could open the door to seeing a community gynecologist who can prescribe Intrarosa under your VA community care authorization.

Step 4: Use the VA Community Care Network

If your VA facility denies coverage and you qualify under Mission Act criteria (drive time, wait time, or unavailable specialty), VA will authorize you to see a community provider. That provider can prescribe Intrarosa, and you submit the prescription to a VA-authorized community pharmacy for reimbursement. VA Community Care eligibility criteria are published here.

Cost Outside VA: Cash Pay, Insurance, and Coupons

Even if you cannot get Intrarosa through VA, you have several pathways to reduce the $230 average cash price.

Manufacturer Savings Program

Millicent Pharma offers a savings card for commercially insured patients. As of early 2026, eligible patients may pay as little as $0 for a limited number of fills. Savings programs change frequently; verify the current offer directly at the Intrarosa manufacturer website or by calling the number on the packaging before assuming any specific discount applies.

Savings cards typically do not work for federally funded coverage including Medicare, Medicaid, TRICARE, and VA. If you are a veteran using TRICARE rather than VA pharmacy benefits, check TRICARE's formulary status separately, as TRICARE's drug coverage differs from VA's.

GoodRx and Pharmacy Discount Cards

At large retail chains, GoodRx and similar discount cards can reduce Intrarosa's price to $180-$210 in some zip codes. This does not require insurance. You present the discount card at checkout instead of insurance. These prices shift by region and pharmacy, so always compare before filling.

Compounded Vaginal DHEA

Compounded vaginal DHEA inserts or suppositories are prepared by licensed 503A compounding pharmacies to match or approximate the prasterone formulation. Depending on your insurance, a prescriber's office membership program, or a direct-pay compounding pharmacy, the cost can approach $0 or a low flat fee per month.

Compounded products are not FDA-approved and are not subject to the same manufacturing oversight as brand-name Intrarosa. The FDA distinguishes between FDA-approved drugs and compounded preparations, noting that compounded drugs lack pre-market review for efficacy and safety. Discuss this tradeoff with your clinician. For many women, the cost savings make compounded DHEA a reasonable choice; for others, the FDA-approved formulation is preferred.

Medicare Part D

Intrarosa has coverage on some Medicare Part D formularies, though it is often placed in a higher tier requiring prior authorization. The Medicare Plan Finder tool lets you compare which Part D plans in your area cover prasterone and at what cost-sharing level. If you are a veteran using Medicare alongside VA, coordinate with your VA social worker or pharmacy team to determine which payer should be primary for this specific drug.

Sex-Specific Pharmacology: How Prasterone Works in Your Body

Prasterone is itself a naturally occurring adrenal androgen. Circulating DHEA levels in women peak in the mid-20s and decline about 10 percent per decade, reaching roughly 10-20 percent of peak values by the mid-60s. This decline affects vaginal tissue, which expresses all the enzymes needed to convert DHEA into estrone, estradiol, and testosterone locally.

Because conversion happens inside vaginal cells (intracrinology), prasterone avoids the first-pass hepatic metabolism that affects oral hormones and produces minimal systemic hormonal exposure. In the Labrie et al. 2016 SYNOPSIS trial published in Menopause, serum DHEA-S, testosterone, estrone, and estradiol all stayed within postmenopausal reference ranges during 12 weeks of nightly use.

Cycle and Hormonal Context

For perimenopausal women who still have cycles but are experiencing GSM symptoms, the data on prasterone are limited. Most trial data come from postmenopausal women (no menses for 12 months). If you are perimenopausal, your clinician may consider low-dose vaginal estrogen or a vaginal moisturizer first, given the stronger evidence base in this life stage. Still, some perimenopausal women with hormonally sensitive conditions (certain breast cancer histories, for instance) ask about prasterone specifically because of its local mechanism. Discuss this with your gynecologist or menopause specialist.

Side Effects Women Report Most

In clinical trials, the most common adverse event was vaginal discharge, reported by about 8.8 percent of prasterone users versus 3.5 percent of placebo users. This is typically a thin, whitish discharge from increased vaginal secretions as the epithelium regenerates. It is not a sign of infection.

Other reported effects include:

• Abnormal Pap smear findings (transient, related to epithelial maturation changes)
• Vaginal discomfort on insertion, especially in severely atrophic tissue
• Rarely, mild androgenic effects such as acne if serum androgen levels rise above the postmenopausal range

Women with a personal history of androgen-sensitive conditions such as polycystic ovary syndrome (PCOS), acne, or hirsutism should discuss the theoretical androgenic exposure with their provider, though the clinical significance is considered low given the local action of the drug.

Pregnancy, Lactation, and Contraception

Prasterone vaginal inserts are contraindicated in pregnancy. DHEA is a precursor to both estrogen and androgen, and its effects on fetal development are not established. The FDA prescribing information for Intrarosa states the drug should not be used during pregnancy.

If you are trying to conceive, do not use Intrarosa. Vaginal dryness during fertility treatment or the luteal phase can be managed with fertility-safe vaginal moisturizers (such as Replens) or lubricants; discuss options with your reproductive endocrinologist.

Lactation: Prasterone has no published human lactation data. Given that DHEA can be converted to hormones that may suppress prolactin or alter milk composition, the general recommendation is to avoid use during breastfeeding. Postpartum vaginal atrophy (a real and common problem) may be addressed with non-hormonal vaginal lubricants until breastfeeding ends.

Contraception: Intrarosa is indicated only for postmenopausal women, who by definition are not at risk of pregnancy. For women undergoing medically induced menopause (chemotherapy, GnRH agonists) who may still be fertile, reliable contraception is required during any hormonal treatment. Discuss your specific situation with your oncologist and gynecologist.

Who This Treatment Is Right For, and Who Should Look Elsewhere

Good candidates for prasterone vaginal inserts

• Postmenopausal women with moderate-to-severe dyspareunia or vaginal dryness who want a non-systemic option
• Women with a personal or family history of breast cancer who have been counseled by their oncologist that local vaginal therapy is acceptable (prasterone's low systemic absorption is relevant here, though no long-term oncology safety data exist in this population)
• Women who have tried vaginal estrogen and experienced breakthrough bleeding, systemic symptoms, or tolerance issues
• Perimenopausal women with severe GSM symptoms after shared decision-making with a menopause-trained provider

Women who should consider alternatives first

• Women in reproductive years who have not yet reached perimenopause (evidence base is postmenopausal)
• Pregnant women (contraindicated)
• Women who are breastfeeding (insufficient safety data)
• Women whose GSM is mild and responds to over-the-counter vaginal moisturizers (no need for a prescription product)
• Women with known or suspected androgen-sensitive tumors

The Menopause Society's 2023 position statement on GSM notes that all approved local vaginal therapies, including prasterone, vaginal estradiol, and ospemifene, are effective and the choice among them should be individualized based on patient preference, medical history, and cost.

Comparing Intrarosa to Other GSM Treatments

You have several options in the same therapeutic space. Here is how they compare practically:

| Treatment | Route | Systemic exposure | Typical cost | VA formulary | |---|---|---|---|---| | Vaginal estradiol cream or ring | Vaginal | Very low | $30-$80 | Often covered | | Vaginal estradiol tablet (Vagifem, generic) | Vaginal | Very low | $40-$100 generic | Often covered | | Prasterone (Intrarosa) | Vaginal insert | Minimal | ~$230 brand | Non-formulary | | Ospemifene (Osphena) | Oral | Systemic SERM | ~$200-$300 | Non-formulary | | Compounded vaginal DHEA | Vaginal | Minimal | ~$20-$60 | Not applicable | | Non-hormonal moisturizers | Vaginal | None | $10-$20 OTC | Not applicable |

Vaginal estrogen remains the most widely studied and recommended first-line treatment for GSM according to ACOG Practice Bulletin 141, and generic vaginal estradiol is typically on VA formulary. For many women, starting there is the path of least resistance on cost and access, then escalating to prasterone if estrogen is not tolerable or is contraindicated.

Documentation Tips to Strengthen Your VA Non-Formulary Request

Your provider's ability to get Intrarosa approved through VA depends heavily on how the clinical note is written. Here is what to ask your provider to include:

• The specific GSM symptom cluster and severity score (use the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire if available)
• Prior treatment history: which formulary options were tried, at what doses, for how long, and why they were discontinued
• Why prasterone specifically addresses a clinical need that formulary options cannot (for example, prior intolerance to vaginal estrogen, or oncology team's recommendation for a non-estrogenic option)
• A note that the patient has been counseled on the non-formulary status and cost implications

The VA Women's Health Program clinical guidance supports individualized menopause care, which provides a policy anchor for your provider's note.

A Note on the Evidence Gap in Women Veterans

Women veterans represent approximately 10 percent of the total veteran population and are the fastest-growing demographic using VA services, yet women were underrepresented in many of the foundational menopause and GSM trials. The SYNOPSIS trial that supported Intrarosa's FDA approval enrolled postmenopausal women in the general population; it did not specifically study combat veterans, women with PTSD, or women on medications common in the veteran population (SSRIs, antipsychotics, opioids) that may interact with GSM symptoms or sexual function.

This is a real evidence gap. When your provider weighs the data, the applicability to your specific history as a veteran may be imperfect. Ask your clinician explicitly: what does the evidence say for someone with my health history? That question is not a challenge to their expertise; it is the right thing to ask.

Practical Next Steps

If you are a woman veteran dealing with GSM symptoms and want to pursue Intrarosa through VA:

1. Schedule with VA Women's Health Clinic specifically, not general primary care if possible. Women's health providers at VA are more likely to be current on GSM options.
2. Bring a symptom diary covering frequency and severity of vaginal dryness, burning, and dyspareunia over the past 4 weeks.
3. Ask your provider to document prior treatment attempts with formulary alternatives, even if those attempts were brief or informal.
4. Check the current Millicent savings program before your appointment so you know your cash-pay fallback.
5. Ask about compounded vaginal DHEA from a 503A pharmacy if the brand is repeatedly denied; your VA provider can write an outside prescription.
6. Verify your TRICARE status. If you use TRICARE as primary rather than VA pharmacy, check the TRICARE formulary at tricare.mil because TRICARE's formulary decisions differ from VA's.

All programs and formulary decisions change. Verify current VA formulary status and any manufacturer discount program directly before your appointment.